Advertisement

Oxygen Therapeutics (“Blood Substitutes”)

Where are they, and what can we expect?
  • Peter E. Keipert
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 540)

Abstract

For almost a century, scientists have been pursuing the development of “artificial blood” — seeking a product that would be safe, universally compatible with all blood types, and readily available. The commercial development of hemoglobin (Hb) and perfluorochemical (PFC) based oxygen carriers over the past 30 years has followed a rather complex pathway characterized by early promises, safety concerns, frequent setbacks, and the potential for major commercial success. Along the way, however, various preclinical efficacy studies have revealed that these products are truly oxygen therapeutics and that they may be more than just temporary “blood substitutes”. While they clearly have the potential to radically alter blood transfusion practice, their ability to deliver oxygen to tissues in ways that differ from and are more efficient than red blood cells make them attractive drugs for use in a variety of clinical situations and medical conditions where vital tissues are at risk of acute hypoxia.

Keywords

West Nile Virus Bovine Spongiform Encephalopathy Allogeneic Blood Blood Substitute Hemoglobin Solution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L.T. Goodnough, M.E. Brecher, M.H. Kanter, and J.P. AuBuchon, Transfusion medicine: Part 1. Blood transfusion, N. Eng. J. Med. 340, 438–447 (1999).CrossRefGoogle Scholar
  2. 2.
    L. Tan, M.A. Williams, M.K. Khan, et al., Risk of transmission of bovine spongiform encephalopathy -to humans in the United States, JAMA 281, 2330–2339 (1999).PubMedCrossRefGoogle Scholar
  3. 3.
    M. Contreras and J.A. Babara, Infections related to red cell transfusions including variant Creutzfeld-Jakob disease, TATM3, 5–12 (2000).Google Scholar
  4. 4.
    P.C. Hebert, G. Wells, M.A. Blajchman, et al., A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care (TRICC) Investigators, Canadian Critical Care Group, N. Engl. J. Med. 340, 409–417 (1999).PubMedCrossRefGoogle Scholar
  5. 5.
    R. Regan and.0 Taylor, Blood transfusion medicine, Brit. Med. J. 325, 143–147 (2002).PubMedCrossRefGoogle Scholar
  6. 6.
    A.W. Sellards and G.R. Minot, Injection of hemoglobin in man and its relation to blood destruction, with special reference to the anemias, J. Med. Res. 34, 469–494 (1916).PubMedGoogle Scholar
  7. 7.
    S.F. Rabiner, J.R. Helbert, H. Lopas, and L.H. Friedman, Evaluation of a stroma-free hemoglobin solution for use as a plasma expander, J. Exp. Med. 126, 1127–1142 (1967).PubMedCrossRefGoogle Scholar
  8. 8.
    J.P. Savitsky, J. Doczi, J. Black, and J.D. Arnold, A clinical safety trial of stroma-free hemoglobin, Clin. Pharmacol. 7her. 23, 73–80 (1978).Google Scholar
  9. 9.
    G.S. Moss, S.A. Gould, A.L. Rosen, L.R. Sehgal, and H.L. Sehgal, Results of the first clinical trial with a polymerized hemoglobin solution, Biomater. Artif. Cells Artif. Organs 17, 633 (1989).Google Scholar
  10. 10.
    R.M. Winslow, Hemoglobin-based Red Cell Substitutes ( The Johns Hopkins University Press, Baltimore and London, 1992 ).Google Scholar
  11. 11.
    L.C. Clark and R. Gollan, Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure, Science 152, 1755–1756 (1966).PubMedCrossRefGoogle Scholar
  12. 12.
    R.P. Geyer, R.G. Monroe, and K. Taylor, Survival of rats perfused with a perfluorocarbon-detergent preparation, in: Organ Perfusion and Preservation, edited by J.V. Norman, J. Folkman, L.E. Hardison, L.E. Ridolf, and F.J. Veith ( Appleton-Crofts, New York, 1968 ), pp. 85–95.Google Scholar
  13. 13.
    K. Yokoyama, K. Yamanouchi, M. Watanabe, et al., Preparation of perfluorodecalin emulsion; an approach to the red cells substitute, Fed. Proc. 34, 1478–1483 (1975).PubMedGoogle Scholar
  14. 14.
    P.E. Keipert, Perfluorochemical Emulsions - Future Alternatives to Transfusion, in: Blood Substitutes: Principles, Methods, Products and Clinical Trials, edited by T.M.S. Chang ( Karger Landes Systems, Basel, 1998 ), pp. 127–156.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Peter E. Keipert
    • 1
  1. 1.Alliance Pharmaceutical CorpSan DiegoUSA

Personalised recommendations